Major Novartis shareholder calls for board shake-up after drug trial setbacks

Novartis shares suffered a record weekly decline after consecutive clinical-trial setbacks, prompting a major shareholder to call for a board overhaul. The investor argues that governance changes are needed at the Swiss drugmaker, adding management pressure to concerns over its drug-development pipeline.